Semaglutide and the TGA: Australian Approval Status

Semaglutide is registered on the ARTG (Australian Register of Therapeutic Goods) via two brand names with distinct approved indications. Ozempic (semaglutide injection 0.5, 1.0, 1.4 mg/week) is registered for type 2 diabetes mellitus, approved for adults with inadequate glycaemic control. Wegovy (semaglutide injection 0.25, 0.5, 1.0, 1.7, 2.4 mg/week) is registered for chronic weight management, approved for adults with obesity (BMI ≥30 kg/m²) or overweight with weight-related comorbidities (BMI ≥27 kg/m²). Both products are prescription-only medicines requiring a doctor's prescription; they are not available over-the-counter.

The TGA evaluates therapeutic goods for quality (pharmaceutical manufacturing standards), safety (toxicology, clinical adverse event data), and efficacy (clinical trial evidence). Semaglutide met these criteria for approval based on evidence from the SUSTAIN program (diabetes) and STEP program (weight management). Both indications were approved through standard regulatory pathways, not expedited or conditional approvals.

Ozempic (semaglutide for type 2 diabetes) has been available in Australia since 2018 under the TGA approval for glycaemic control in type 2 diabetes. The product is dosed 0.5–1.4 mg subcutaneously once weekly, with dose escalation according to clinical response. Ozempic is available through general practitioner and specialist (endocrinologist, general medicine) prescriptions. The medication is subsidised by the Pharmaceutical Benefits Scheme (PBS) under specific criteria, making it accessible to eligible patients at reduced cost.

Wegovy (semaglutide for chronic weight management) received TGA approval more recently (2021), reflecting regulatory recognition of obesity as a medical disease warranting pharmacotherapy. Wegovy is dosed 0.25–2.4 mg subcutaneously once weekly for weight management. Unlike Ozempic, Wegovy is not listed on the PBS and is typically accessed through private prescriptions, with costs borne by patients or private health insurance. Some private insurance schemes may provide coverage for Wegovy; patients should check their insurance policy.

The TGA operates under the Therapeutic Goods Act 1989 and applies the Australian Code of Good Manufacturing Practice (GMP). For semaglutide, the TGA reviewed manufacturing facilities (Novo Nordisk), analytical methods (identity, purity, potency testing), stability data, nonclinical toxicology (including the thyroid C-cell studies), and clinical safety/efficacy data. The diabetes indication approval relied on the SUSTAIN program (primarily SUSTAIN 1–6); the obesity indication approval relied on the STEP program. Both approvals required demonstration of benefit exceeding risks.

Post-approval, the TGA monitors therapeutic goods through the adverse event reporting system (TGASRS and other reporting pathways). Australian healthcare providers, patients, and manufacturers can report adverse events to the TGA. This pharmacovigilance system enables detection of safety signals that emerge during post-marketing use. For semaglutide, no unexpected safety signals have been identified in the Australian post-marketing period (since 2018 for Ozempic; since 2021 for Wegovy).

Ozempic (diabetes indication) is listed on the PBS under specific criteria: patients must have type 2 diabetes inadequately controlled by other antidiabetic medications and meet clinical appropriateness criteria. PBS-listed patients pay a patient co-payment (approximately AUD $50–$70 per script as of 2026, subject to annual updates), with the government subsidy covering the remainder of the cost. Specialists and GPs can prescribe; GPs typically initiate therapy in primary care, with specialist review available for complex cases.

Wegovy (weight management indication) is not PBS-listed in Australia as of 2026, meaning it is accessed through private prescriptions only. Out-of-pocket costs are substantial (approximately AUD $400–$600 per month for the 2.4 mg maintenance dose, varying by pharmacy). Some Australian patients have accessed semaglutide through private prescription pathways or by travelling to other countries for treatment. Discussion of cost and access barriers is recommended during patient counselling.

In Australia, semaglutide prescriptions can be issued by general practitioners, endocrinologists, and other registered medical practitioners. While specialist initiation is not mandatory for Ozempic (diabetes), some GPs may refer patients to specialists for dose titration and monitoring, particularly if patients have comorbidities (cardiovascular disease, renal impairment) or prior pancreatitis. Prescribers should assess baseline renal function, thyroid history, and pancreatitis risk; baseline thyroid examination and TSH may be considered depending on individual risk factors.

Off-label use (e.g., using Ozempic for weight management in non-diabetic obese patients) is technically possible but not supported by TGA approval; patients considering off-label use should discuss risks and benefits with their prescriber. Some practitioners may provide off-label prescriptions, particularly if Wegovy is unavailable or unaffordable, but this practice exists in a regulatory grey area. The TGA's position on off-label use is that it remains a clinical decision between provider and patient, but the product is not formally approved for off-label indications.